Decreased homovanillic acid concentrations in cerebrospinal fluid in children without a known defect in dopamine metabolism

European Journal of Paediatric Neurology

Volumn 7, Issue 1, 2003, Pages 31-37

  Van Der Heyden, J C ^a   Rotteveel, J J ^a   Wevers, R A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cerebrospinal fluid; Children; Dopamine metabolism; Homovanillic acid concentration

Indexed keywords

DOPAMINE; HOMOVANILLIC ACID;

ADOLESCENT; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHILD; CLINICAL FEATURE; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DOPAMINE METABOLISM; DOPAMINE UPTAKE; ENZYME DEFICIENCY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INFANT; MAJOR CLINICAL STUDY; METABOLIC DISORDER; METABOLITE; PRIORITY JOURNAL; PUNCTURE; RETROSPECTIVE STUDY; SYMPTOM;

EID: 0037214695     PISSN: 10903798     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1090-3798(02)00137-X     Document Type: Article

References (26)

1. Wevers RA, de Rijk-van Andel JF, Bräutigam C et al. A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC). J Inher Metab Dis 1999;22:364-73.
2. Blennow K, Wallin A, Gottfries CG et al. Concentration gradients for monoamine metabolites in lumbar CSF. J Neural Transm 1993;5:5-15.
3. Hildebrand J, Bourgeois F, Buyse M et al. Reproducibility of monoamine metabolite measurements in human CSF. Acta Neurol Scand 1990;81:427-30.
4. Lamers KJB, Wevers RA. Abnormalities of biogenic amines affecting the metabolism of serotonin and catecholamines. Multiple Sclerosis 1998;4:37-8.
5. Hartikainen P, Soininen H, Reinikainen KJ et al. Neurotransmitter markers in the CSF of normal subjects. Effects of aging and other confounding factors. J Neural Transm 1991;84:103-17.
6. Blennow K, Wallin A, Gottfries CG et al. CSF monoamine metabolites in 114 healthy individuals 18-88 years of age. Eur Neuropsychopharmacol 1993;3:55-61.
7. Degrell I, Nagy E. Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in CSF. Biol Psychol 1990;27:891-6.
8. Hyland K, Surtees RAH, Rodeck C, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 1992;42:1980-8.
9. de Rijk-van Andel JF, Wevers RA, Jansen RJT et al. Parkinson syndroom op de zuigelingen leeftijd. NTVG 2000;5:322-7.
10. Shaywitz BA, Cohen DJ, Bowers MB. Reduced CSF 5-HIAA and HVA in children with epilepsy. Neurology 1975;25:72-9.
11. Devinsky O, Emoto S, Goldstein DS et al. CSF and serum levels of DOPA, catechols, and monoamine metabolites in patients with epilepsy. Epilepsia 1992;33:263-70.
12. Giroud M, Dumas R, Dauvergne M et al. 5-HIAA and HVA in CSF of children with febrile convulsions. Epilepsia 1990;31:178-81.
13. Papeschi R, Molina-Negro P, Sourkes TL, Erba G. The concentration of HVA and 5-HIAA in ventricular and lumbar CSF. Neurology 1972;22:1151-9.
14. Tabaddor K, Wolfson LI, Sharpless NS. Diminished ventricular fluid dopamine metabolites in adult-onset dystonia. Neurology 1978;28:1254-8.
15. Dobyns WB, Ozelius LJ, Kramer PL et al. Rapid-onset dystonia-parkinsonism. Neurology 1993;43:2596-602.
16. Stahl SM, Faull KF, Barchas JD, Berger PA. CSF monoamine metabolites in movement disorders and normal aging. Arch Neurol 1985;42:166-9.
17. Banki CM, Vojnik M, Molnar G. CSF amine metabolites, tryptophan and clinical parameters in depression. Part 1. Background variables. J Aff Disord 1981;3:81-9.
18. Banki CM, Vojnik M, Molnar G. CSF amine metabolites, tryptophan and clinical parameters in depression. Part 2. Psychopathological symptoms. J Aff Disord 1981;3:91-9.
19. Sjögren M, Minthon L, Passant U et al. Decreased monoamine metabolites in frontotemporal dementia and alzheimer's disease. Neurobiol Aging 1998;19:379-84.
20. Westerink BHC. Correlation between high-performance liquid chromatography and automated fluorimetric methods for the determination of dopamine, 3,4-dihydrophenylacetic acid, HVA and 5-HIAA acid in nervous tissue and CSF. J Chrom 1982;233:69-77.
21. Bräutigam C, Wevers RA, Jansen RJT et al. Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 1998;44:1897-904.
22. Angelini L, Nardocci N, Rumi V et al. Hallervorden-Spatz disease: clinical and MRI study of 11 cases diagnosed in life. J Neurol 1992;239:417-25.
23. Tedeschi G, Bonavita S, Barton NW et al. Proton MRS imaging in the clinical evaluation of patients with Niemann-Pick type C disease. J Neurol Neurosurg Psych 1998;65:72-9.
24. 18F] Fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis. J Neurol Neurosurg Psych 1997;62:622-5.
25. Habel A, Yates CM, McQueen JK et al. HVA and 5-HIAA in CSF in children with afebrile and febrile convulsions. Neurology 1981;31:488-91.
26. Louw D, Sutherland GR, Glavin GB, Girvin J. A study of monoamine metabolism in human epilepsy. Can J Neurol Sci 1989;16:394-7.